JP2020128412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020128412A5 JP2020128412A5 JP2020084402A JP2020084402A JP2020128412A5 JP 2020128412 A5 JP2020128412 A5 JP 2020128412A5 JP 2020084402 A JP2020084402 A JP 2020084402A JP 2020084402 A JP2020084402 A JP 2020084402A JP 2020128412 A5 JP2020128412 A5 JP 2020128412A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- ethyl
- subject
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 13
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 8
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 8
- DSQFSRAJFCOGKA-GKFVBPDJSA-N (5z,8z,11z,14z)-2-ethylicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCC(CC)C(O)=O DSQFSRAJFCOGKA-GKFVBPDJSA-N 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- CLWMCOKPVIXYQL-UHFFFAOYSA-N 2-ethyldocosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=C(CC)C(O)=O CLWMCOKPVIXYQL-UHFFFAOYSA-N 0.000 claims 2
- 206010014486 Elevated triglycerides Diseases 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
- YBKSMWBLSBAFBQ-UHFFFAOYSA-N ethyl arachidate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC YBKSMWBLSBAFBQ-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- RRRQMBRDGQTXCC-UHFFFAOYSA-N ethyl nonadeca-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC RRRQMBRDGQTXCC-UHFFFAOYSA-N 0.000 claims 2
- GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 claims 2
- 229960002600 icosapent ethyl Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31044310P | 2010-03-04 | 2010-03-04 | |
| US61/310,443 | 2010-03-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207855A Division JP2019048843A (ja) | 2010-03-04 | 2018-11-05 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020128412A JP2020128412A (ja) | 2020-08-27 |
| JP2020128412A5 true JP2020128412A5 (enExample) | 2022-07-20 |
| JP7136526B2 JP7136526B2 (ja) | 2022-09-13 |
Family
ID=44531868
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556265A Active JP6327497B2 (ja) | 2010-03-04 | 2011-03-04 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2016183057A Pending JP2017025089A (ja) | 2010-03-04 | 2016-09-20 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2018207855A Pending JP2019048843A (ja) | 2010-03-04 | 2018-11-05 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020084402A Active JP7136526B2 (ja) | 2010-03-04 | 2020-05-13 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2020124388A Pending JP2020183428A (ja) | 2010-03-04 | 2020-07-21 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556265A Active JP6327497B2 (ja) | 2010-03-04 | 2011-03-04 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2016183057A Pending JP2017025089A (ja) | 2010-03-04 | 2016-09-20 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
| JP2018207855A Pending JP2019048843A (ja) | 2010-03-04 | 2018-11-05 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020124388A Pending JP2020183428A (ja) | 2010-03-04 | 2020-07-21 | 心血管疾患を処置及び／又は予防するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (10) | US20110218243A1 (enExample) |
| EP (2) | EP2542060B1 (enExample) |
| JP (5) | JP6327497B2 (enExample) |
| KR (1) | KR20130026428A (enExample) |
| AU (1) | AU2011222544A1 (enExample) |
| BR (1) | BR112012022336A2 (enExample) |
| CA (4) | CA3043081C (enExample) |
| ES (1) | ES2750365T3 (enExample) |
| MX (1) | MX337315B (enExample) |
| PH (3) | PH12012501755A1 (enExample) |
| RU (3) | RU2606853C2 (enExample) |
| SG (1) | SG183883A1 (enExample) |
| WO (1) | WO2011109724A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3187182B1 (en) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| KR101343249B1 (ko) | 2009-04-29 | 2013-12-19 | 아마린 파마, 인크. | 안정한 제약 조성물 및 그의 사용 방법 |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
| EP2542060B1 (en) * | 2010-03-04 | 2019-10-02 | Amarin Pharmaceuticals Ireland Limited | Compositions for treating and/or preventing cardiovascular disease |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ757815A (en) | 2010-11-29 | 2020-05-29 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| JP6307442B2 (ja) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法 |
| CA2916208A1 (en) * | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| WO2014004993A2 (en) * | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing ldl-p |
| WO2014004861A2 (en) * | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating pediatric metabolic syndrome |
| FI3815684T3 (fi) | 2012-06-29 | 2024-09-30 | Amarin Pharmaceuticals Ie Ltd | Menetelmiä sydän- ja verisuoniperäisen tapahtuman riskin alentamiseksi statiinihoitoa saavassa kohteessa |
| US20150258050A1 (en) * | 2012-10-23 | 2015-09-17 | Deakin University | Method for reducing triglycerides |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140221676A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015066512A1 (en) * | 2013-10-31 | 2015-05-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| AU2022263358A1 (en) * | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN113346980B (zh) * | 2021-08-02 | 2023-08-11 | 浙江国利信安科技有限公司 | 用于消息转发的方法、电子设备和计算机存储介质 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377526A (en) * | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
| US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| IE63225B1 (en) * | 1988-09-13 | 1995-04-05 | Efamol Holdings | Use of fatty acids in the treatment of myalgic encephalomyelitis |
| US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| JP2839276B2 (ja) * | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
| US5215630A (en) * | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
| DE4133694C2 (de) * | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
| JP3400466B2 (ja) * | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
| JPH0649479A (ja) * | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−３不飽和脂肪酸系化合物の安定化法 |
| US5888541A (en) * | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
| GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| AU711482B2 (en) * | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
| IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| JPH0959206A (ja) * | 1995-08-25 | 1997-03-04 | Nippon Oil & Fats Co Ltd | エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法 |
| GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
| KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
| JP4309045B2 (ja) * | 1997-10-30 | 2009-08-05 | 森下仁丹株式会社 | 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法 |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
| DE59914760D1 (de) * | 1999-07-28 | 2008-06-26 | Swiss Caps Rechte & Lizenzen | Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung |
| CA2382262C (en) * | 1999-08-30 | 2004-12-07 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| JP4170542B2 (ja) * | 1999-11-18 | 2008-10-22 | 日油株式会社 | 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体 |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| CN1268328C (zh) * | 2001-05-30 | 2006-08-09 | 拉克斯戴尔有限公司 | 辅酶q与二十碳五烯酸(epa) |
| ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| US20030166614A1 (en) * | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
| AU2003257550A1 (en) * | 2002-08-20 | 2004-03-11 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
| NZ540154A (en) * | 2002-11-22 | 2008-07-31 | Nippon Suisan Kaisha Ltd | External composition containing polyunsaturated fatty acid or its salt or ester |
| US20070105954A1 (en) * | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| EP1833313A2 (en) * | 2004-10-15 | 2007-09-19 | Corporation Limited Photonz | Compositions containing high omega-3 and low saturated fatty acid levels |
| JP2008522970A (ja) * | 2004-12-06 | 2008-07-03 | レリアント ファーマスーティカルズ インコーポレイテッド | 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤 |
| US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| US20070104779A1 (en) * | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
| JP2009520824A (ja) * | 2005-12-20 | 2009-05-28 | セネストラ エルエルシー | オメガ３脂肪酸製剤 |
| ES2448424T3 (es) * | 2006-02-07 | 2014-03-13 | Mochida Pharmaceutical Co., Ltd. | Composición para prevenir la recurrencia de accidente cerebrovascular |
| CA2653787C (en) * | 2006-05-31 | 2016-06-21 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| NZ573719A (en) * | 2006-07-05 | 2011-08-26 | Photonz Corp Ltd | Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis |
| US20090304784A1 (en) * | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
| US20080125490A1 (en) * | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
| LT3037089T (lt) * | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
| EP3318255B1 (en) * | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| EP2542060B1 (en) * | 2010-03-04 | 2019-10-02 | Amarin Pharmaceuticals Ireland Limited | Compositions for treating and/or preventing cardiovascular disease |
-
2011
- 2011-03-04 EP EP11751431.5A patent/EP2542060B1/en active Active
- 2011-03-04 CA CA3043081A patent/CA3043081C/en active Active
- 2011-03-04 WO PCT/US2011/027218 patent/WO2011109724A1/en not_active Ceased
- 2011-03-04 BR BR112012022336-4A patent/BR112012022336A2/pt not_active Application Discontinuation
- 2011-03-04 CA CA3066588A patent/CA3066588C/en active Active
- 2011-03-04 CA CA2792090A patent/CA2792090C/en active Active
- 2011-03-04 CA CA3147657A patent/CA3147657C/en active Active
- 2011-03-04 JP JP2012556265A patent/JP6327497B2/ja active Active
- 2011-03-04 SG SG2012065215A patent/SG183883A1/en unknown
- 2011-03-04 RU RU2012142181A patent/RU2606853C2/ru active
- 2011-03-04 RU RU2016129266A patent/RU2728825C2/ru active
- 2011-03-04 AU AU2011222544A patent/AU2011222544A1/en not_active Abandoned
- 2011-03-04 US US13/040,977 patent/US20110218243A1/en not_active Abandoned
- 2011-03-04 KR KR1020127024878A patent/KR20130026428A/ko not_active Ceased
- 2011-03-04 EP EP19190599.1A patent/EP3583849A1/en active Pending
- 2011-03-04 MX MX2012010253A patent/MX337315B/es active IP Right Grant
- 2011-03-04 PH PH1/2012/501755A patent/PH12012501755A1/en unknown
- 2011-03-04 ES ES11751431T patent/ES2750365T3/es active Active
-
2013
- 2013-08-28 US US14/012,625 patent/US20140128464A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,799 patent/US20150335607A1/en not_active Abandoned
-
2016
- 2016-09-20 JP JP2016183057A patent/JP2017025089A/ja active Pending
-
2017
- 2017-01-23 US US15/413,093 patent/US20170128406A1/en not_active Abandoned
-
2018
- 2018-04-19 PH PH12018500843A patent/PH12018500843B1/en unknown
- 2018-11-05 JP JP2018207855A patent/JP2019048843A/ja active Pending
-
2019
- 2019-05-06 US US16/404,558 patent/US20200297681A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084402A patent/JP7136526B2/ja active Active
- 2020-07-08 US US16/923,311 patent/US20200360330A1/en not_active Abandoned
- 2020-07-17 RU RU2020123679A patent/RU2020123679A/ru unknown
- 2020-07-21 JP JP2020124388A patent/JP2020183428A/ja active Pending
-
2021
- 2021-01-19 US US17/151,956 patent/US20210260016A1/en not_active Abandoned
- 2021-01-21 US US17/154,357 patent/US20210386701A1/en not_active Abandoned
- 2021-04-06 PH PH12021550756A patent/PH12021550756A1/en unknown
- 2021-12-03 US US17/457,579 patent/US20220323393A1/en not_active Abandoned
-
2024
- 2024-03-13 US US18/603,789 patent/US20240216322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020128412A5 (enExample) | ||
| JP2019048843A5 (enExample) | ||
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| JP6173437B2 (ja) | スタチン及びω−３脂肪酸の組成物 | |
| RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JPWO2020037153A5 (enExample) | ||
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| US20110251275A1 (en) | Omega-3 fatty acids for reduction of lp-pla2 levels | |
| JP2013521310A5 (enExample) | ||
| RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| JP2015503590A5 (enExample) | ||
| WO2007007686A1 (ja) | 心血管イベント発症予防用組成物 | |
| JP2023153863A (ja) | １５－ｈｅｐｅを含む組成物及びその使用方法 | |
| WO2007091338A1 (ja) | 脳卒中再発予防用組成物 | |
| JP2012516852A5 (enExample) | ||
| JP2003508484A5 (enExample) | ||
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| WO2012112531A1 (en) | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases | |
| SG181446A1 (en) | Combination composition useful for treating cardiovascular diseases | |
| JP6469261B2 (ja) | 多価不飽和遊離脂肪酸を含むミリカプセル製剤 | |
| JP2009544701A (ja) | オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 | |
| EP2674157A1 (en) | Therapeutic agent for diastolic congestive heart failure | |
| US20140314844A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| MX2011001419A (es) | Tratamiento a largo plazo de deficiencia cardiaca sintomatica. |